{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T09:10:31Z","timestamp":1779095431029,"version":"3.51.4"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007446","name":"King Khalid University","doi-asserted-by":"publisher","award":["RA\/KKU\/10\/46"],"award-info":[{"award-number":["RA\/KKU\/10\/46"]}],"id":[{"id":"10.13039\/501100007446","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.diabres.2026.113155","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:41:39Z","timestamp":1771000899000},"page":"113155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The impact of GLP-1 and incretin-based therapies on counterregulatory responses to hypoglycemia in diabetes mellitus: mechanisms and clinical implications"],"prefix":"10.1016","volume":"233","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1940-1296","authenticated-orcid":false,"given":"Pitchai","family":"Balakumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noohu Abdulla","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vigneshwaran","family":"Easwaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid M.","family":"Orayj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2026.113155_b0005","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.phrs.2016.09.040","article-title":"Prevalence and prevention of cardiovascular disease and diabetes mellitus","volume":"113","author":"Balakumar","year":"2016","journal-title":"Pharmacol Res"},{"issue":"10467","key":"10.1016\/j.diabres.2026.113155_b0010","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(24)02422-X","article-title":"Rising diabetes, lagging treatment, and the need for better systems","volume":"404","author":"Guariguata","year":"2024","journal-title":"Lancet"},{"issue":"10397","key":"10.1016\/j.diabres.2026.113155_b0015","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","author":"GBD 2021 Diabetes Collaborators","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2026.113155_b0020","unstructured":"NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. Lancet. 2024;404(10467):2077-2093."},{"issue":"4","key":"10.1016\/j.diabres.2026.113155_b0025","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1080\/14737167.2020.1782748","article-title":"Burden of disease and costs associated with type 2 diabetes in emerging and established markets: systematic review analyses","volume":"21","author":"Alzaid","year":"2021","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"8","key":"10.1016\/j.diabres.2026.113155_b0030","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.3390\/jcm10081798","article-title":"Cardiovascular disease in type 1 diabetes mellitus: epidemiology and management of cardiovascular risk","volume":"10","author":"Colom","year":"2021","journal-title":"J Clin Med"},{"issue":"9","key":"10.1016\/j.diabres.2026.113155_b0035","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41574-022-00690-7","article-title":"The burden and risks of emerging complications of diabetes mellitus","volume":"18","author":"Tomic","year":"2022","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"10.1016\/j.diabres.2026.113155_b0040","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/jhm.212","article-title":"Hypoglycemia in hospitalized patients treated with antihyperglycemic agents","volume":"2","author":"Varghese","year":"2007","journal-title":"J Hosp Med"},{"issue":"1","key":"10.1016\/j.diabres.2026.113155_b0045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/nyas.13872","article-title":"Exposure to hypoglycemia and risk of stroke","volume":"1431","author":"Smith","year":"2018","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.diabres.2026.113155_b0050","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12902-020-0518-5","article-title":"Hypoglycemia in patients with type 2 diabetes treated with oral antihyperglycemic agents detected by continuous glucose monitoring: a multi-center prospective observational study in Croatia","volume":"20","author":"Bareti\u0107","year":"2020","journal-title":"BMC Endocr Disord"},{"issue":"10","key":"10.1016\/j.diabres.2026.113155_b0055","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1007\/s00125-020-05223-3","article-title":"Severe hypoglycaemia and absolute risk of cause-specific mortality in individuals with type 2 diabetes: a UK primary care observational study","volume":"63","author":"Zaccardi","year":"2020","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.diabres.2026.113155_b0060","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2337\/dc20-0876","article-title":"Glucose control, sulfonylureas, and insulin treatment in elderly people with type 2 diabetes and risk of severe hypoglycemia and death: an observational study","volume":"44","author":"Ling","year":"2021","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.diabres.2026.113155_b0065","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3143\/geriatrics.60.294","article-title":"A case of repeated severe hypoglycemia caused by accidental ingestion of sulfonylurea in an elderly patient","volume":"60","author":"Yamasaki","year":"2023","journal-title":"Nihon Ronen Igakkai Zasshi"},{"issue":"3","key":"10.1016\/j.diabres.2026.113155_b0070","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/dom.12591","article-title":"Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"18","author":"Nauck","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2026.113155_b0075","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/DMSO.S130834","article-title":"Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research","volume":"10","author":"Levin","year":"2017","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"8","key":"10.1016\/j.diabres.2026.113155_b0080","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.4239\/wjd.v15.i8.1764","article-title":"Intestinal glucagon-like peptide-1: a new player associated with impaired counterregulatory responses to hypoglycaemia in type 1 diabetic mice","volume":"15","author":"Jin","year":"2024","journal-title":"World J Diabetes"},{"key":"10.1016\/j.diabres.2026.113155_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108522","article-title":"Incidence and prevalence of hypoglycaemia in type 1 and type 2 diabetes individuals: a systematic review and meta-analysis","volume":"170","author":"Alwafi","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"issue":"9","key":"10.1016\/j.diabres.2026.113155_b0090","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/dom.12689","article-title":"Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study","volume":"18","author":"Khunti","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.diabres.2026.113155_b0095","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3390\/biomedicines12020391","article-title":"Hypoglycemia unawareness-a review on pathophysiology and clinical implications","volume":"12","author":"H\u00f6lzen","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.diabres.2026.113155_b0100","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwaf236.127","article-title":"Effect of incretin-based therapies on blood pressure: a systematic review and meta-analysis","author":"Basile","year":"2025","journal-title":"Eur J Prev Cardiol"},{"issue":"5","key":"10.1016\/j.diabres.2026.113155_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101470","article-title":"GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes","volume":"49","author":"Monney","year":"2023","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabres.2026.113155_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108904","article-title":"Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: a network meta-analysis","volume":"177","author":"Xia","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"issue":"9","key":"10.1016\/j.diabres.2026.113155_b0115","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/j.cellsig.2013.05.009","article-title":"Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials","volume":"25","author":"Balakumar","year":"2013","journal-title":"Cell Signal"},{"key":"10.1016\/j.diabres.2026.113155_b0120","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3389\/fendo.2020.00178","article-title":"GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials","volume":"11","author":"Gilbert","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10.1016\/j.diabres.2026.113155_b0125","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40200-024-01406-6","article-title":"Narrative review of data supporting alternate first-line therapies over metformin in type 2 diabetes","volume":"23","author":"Andraos","year":"2024","journal-title":"J Diabetes Metab Disord"},{"key":"10.1016\/j.diabres.2026.113155_b0130","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1289643","article-title":"First-line treatment with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in type 2 diabetic population at low risk of cardiovascular disease: a meta-analysis","volume":"15","author":"Deng","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"10.1016\/j.diabres.2026.113155_b0135","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/17446651.2020.1830759","article-title":"Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes","volume":"15","author":"Fr\u00edas","year":"2020","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1016\/j.diabres.2026.113155_b0140","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metab"},{"issue":"1","key":"10.1016\/j.diabres.2026.113155_b0145","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"10.1016\/j.diabres.2026.113155_b0150","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/03007995.2024.2322072","article-title":"Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide","volume":"40","author":"Urva","year":"2024","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"10.1016\/j.diabres.2026.113155_b0155","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.eprac.2024.05.005","article-title":"Switching to tirzepatide 5 mg from glucagon-like peptide-1 receptor agonists: Clinical expectations in the first 12 weeks of treatment","volume":"30","author":"Jabbour","year":"2024","journal-title":"Endocr Pract"},{"issue":"6","key":"10.1016\/j.diabres.2026.113155_b0160","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1007\/s11096-024-01779-x","article-title":"Efficacy and safety of tirzepatide versus placebo in overweight or obese adults without diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"46","author":"Liu","year":"2024","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.diabres.2026.113155_b0165","article-title":"Role of glucagon-like peptide-1 (GLP-1) receptor agonists in hypoglycemia","volume":"14","author":"Ja'arah","year":"2021","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"10.1016\/j.diabres.2026.113155_b0170","doi-asserted-by":"crossref","DOI":"10.1177\/2042018821997320","article-title":"GLP-1 receptor agonists: an updated review of head-to-head clinical studies","volume":"12","author":"Trujillo","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.diabres.2026.113155_b0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18433\/J3G883","article-title":"The efficacy and tolerability of exenatide in comparison to placebo; a systematic review and meta-analysis of randomized clinical trials","volume":"15","author":"Nikfar","year":"2012","journal-title":"J Pharm Pharm Sci"},{"issue":"Suppl 2","key":"10.1016\/j.diabres.2026.113155_b0180","doi-asserted-by":"crossref","first-page":"S279","DOI":"10.2337\/dc11-s231","article-title":"Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability","volume":"34","author":"Garber","year":"2011","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.diabres.2026.113155_b0185","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1345\/aph.1R041","article-title":"Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis","volume":"46","author":"Park","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.diabres.2026.113155_b0190","article-title":"Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis","volume":"353","author":"Salvo","year":"2016","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.diabres.2026.113155_b0195","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1007\/s13300-023-01475-5","article-title":"Challenging clinical perspectives in type 2 diabetes with tirzepatide, a first-in-class twincretin","volume":"14","author":"MacIsaac","year":"2023","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.diabres.2026.113155_b0200","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13098-019-0412-3","article-title":"Hypoglycemia in blood glucose level in type 2 diabetic Japanese patients by continuous glucose monitoring","volume":"11","author":"Hajime","year":"2019","journal-title":"Diabetol Metab Syndr"},{"issue":"6","key":"10.1016\/j.diabres.2026.113155_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2025.101696","article-title":"Are GLP-1 receptor agonists and diabetic retinopathy foes or friends?","volume":"51","author":"Liu","year":"2025","journal-title":"Diabetes Metab"},{"issue":"4","key":"10.1016\/j.diabres.2026.113155_b0210","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/dom.12849","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis","volume":"19","author":"Htike","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.diabres.2026.113155_b0215","article-title":"Glucagon-like peptide analogues for type 2 diabetes mellitus","volume":"2011","author":"Shyangdan","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"18","key":"10.1016\/j.diabres.2026.113155_b0220","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.21037\/atm-21-4162","article-title":"Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data","volume":"9","author":"Zhao","year":"2021","journal-title":"Ann Transl Med"},{"issue":"4","key":"10.1016\/j.diabres.2026.113155_b0225","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2026.113155_b0230","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3389\/fphar.2019.00777","article-title":"Head-to-head comparison of the hypoglycemic efficacy and safety between dipeptidyl peptidase-4 inhibitors and \u03b1-glucosidase inhibitors in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"10","author":"Li","year":"2019","journal-title":"Front Pharmacol"},{"issue":"10300","key":"10.1016\/j.diabres.2026.113155_b0235","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.diabres.2026.113155_b0240","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.14831","article-title":"Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective","volume":"25","author":"De Block","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2026.113155_b0245","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.870722","article-title":"Free versus fixed-ratio combination of basal insulin and GLP-1 receptor agonists in type 2 diabetes uncontrolled with GLP-1 receptor agonists: a systematic review and indirect treatment comparison","volume":"13","author":"Jung","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.diabres.2026.113155_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110828","article-title":"The role of gastric emptying in glucose homeostasis and defense against hypoglycemia: innocent bystander or partner in crime?","volume":"203","author":"De Fano","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"10.1016\/j.diabres.2026.113155_b0255","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2174\/15733998113099990059","article-title":"The science of hypoglycemia in patients with diabetes","volume":"9","author":"Oyer","year":"2013","journal-title":"Curr Diabetes Rev"},{"issue":"6","key":"10.1016\/j.diabres.2026.113155_b0260","first-page":"311","article-title":"Hypoglyk\u00e9mia\u2013v\u00fdskyt, pr\u00edciny a hormon\u00e1lne kontraregulacn\u00e9 mechanizmy u zdrav\u00fdch os\u00f4b a u pacientov s IDDM [Hypoglycemia\u2013occurrence, causes and hormonal counterregulatory mechanisms in healthy persons and in patients with IDDM]","volume":"96","author":"Mok\u00e1n","year":"1995","journal-title":"Bratisl Lek Listy"},{"key":"10.1016\/j.diabres.2026.113155_b0265","doi-asserted-by":"crossref","DOI":"10.1177\/20420188251346260","article-title":"The impact of technology on impaired awareness of hypoglycaemia in type 1 diabetes","volume":"16","author":"Berry","year":"2025","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.diabres.2026.113155_b0270","first-page":"684","article-title":"Evidence for a hypothalamic-pituitary versus adrenal cortical effect of glycemic control on counterregulatory hormone responses to hypoglycemia in insulin-dependent diabetes mellitus","volume":"81","author":"Kinsley","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.diabres.2026.113155_b0275","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.2337\/diacare.21.8.1330","article-title":"Effect of glycemic control on glucose counterregulation during hypoglycemia in NIDDM","volume":"21","author":"Levy","year":"1998","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.diabres.2026.113155_b0280","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2337\/db08-1230","article-title":"Effects of intensive therapy and antecedent hypoglycemia on counterregulatory responses to hypoglycemia in type 2 diabetes","volume":"58","author":"Davis","year":"2009","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.diabres.2026.113155_b0285","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2337\/db08-1647","article-title":"Attenuated sympathoadrenal responses, but not severe hypoglycemia, during aggressive glycemic therapy of early type 2 diabetes","volume":"58","author":"Amiel","year":"2009","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.diabres.2026.113155_b0290","doi-asserted-by":"crossref","first-page":"E1115","DOI":"10.1152\/ajpendo.2001.281.6.E1115","article-title":"Hypoglycemia-associated autonomic failure in diabetes","volume":"281","author":"Cryer","year":"2001","journal-title":"Am J Phys Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.diabres.2026.113155_b0295","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.2337\/diabetes.54.12.3592","article-title":"Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes","volume":"54","author":"Cryer","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2026.113155_b0300","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/9801640","article-title":"Challenges in modelling hypoglycaemia-associated autonomic failure: a review of human and animal studies","volume":"2016","author":"Senthilkumaran","year":"2016","journal-title":"Int J Endocrinol"},{"issue":"3","key":"10.1016\/j.diabres.2026.113155_b0305","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/jim-2017-000582","article-title":"Potential approaches to prevent hypoglycemia-associated autonomic failure","volume":"66","author":"Lontchi-Yimagou","year":"2018","journal-title":"J Invest Med"},{"issue":"2","key":"10.1016\/j.diabres.2026.113155_b0310","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1210\/clinem\/dgae479","article-title":"Effects of intranasal naloxone on hypoglycemia-associated autonomic failure in susceptible individuals","volume":"110","author":"Aleksic","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.diabres.2026.113155_b0315","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3390\/metabo14020100","article-title":"Role of the adrenal medulla in hypoglycaemia-associated autonomic failure-a diabetic perspective","volume":"14","author":"Senthilkumaran","year":"2024","journal-title":"Metabolites"},{"issue":"7","key":"10.1016\/j.diabres.2026.113155_b0320","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1111\/dom.16409","article-title":"Recurrent hypoglycaemia leads to impairment in glucagon-mediated hepatic glycogenolysis in type 1 diabetic mice","volume":"27","author":"Li","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.diabres.2026.113155_b0325","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.4239\/wjd.v15.i12.2394","article-title":"Role of intestinal glucagon-like peptide-1 in impaired counter-regulatory responses to hypoglycemia","volume":"15","author":"Dodamani","year":"2024","journal-title":"World J Diabetes"},{"issue":"1","key":"10.1016\/j.diabres.2026.113155_b0330","doi-asserted-by":"crossref","first-page":"99726","DOI":"10.4239\/wjd.v16.i1.99726","article-title":"Intestinal glucagon-like peptide-1: a new regulator of impaired counterregulatory responses to hypoglycemia in type 1 diabetes mellitus","volume":"16","author":"Liu","year":"2025","journal-title":"World J Diabetes"},{"issue":"2","key":"10.1016\/j.diabres.2026.113155_b0335","doi-asserted-by":"crossref","first-page":"99928","DOI":"10.4239\/wjd.v16.i2.99928","article-title":"Glucagon-like peptide-1 and impaired counterregulatory responses to hypoglycemia in type 1 diabetes","volume":"16","author":"Rocha","year":"2025","journal-title":"World J Diabetes"},{"issue":"3","key":"10.1016\/j.diabres.2026.113155_b0340","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/dom.13570","article-title":"Hypoglycaemia and gastric emptying","volume":"21","author":"Marathe","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.diabres.2026.113155_b0345","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2982.2006.00800.x","article-title":"Relationships between hypoglycaemia and gastric emptying abnormalities in insulin-treated diabetic patients","volume":"18","author":"Lysy","year":"2006","journal-title":"Neurogastroenterol Motil"},{"issue":"8","key":"10.1016\/j.diabres.2026.113155_b0350","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1210\/jc.2005-0513","article-title":"Insulin-induced hypoglycemia accelerates gastric emptying of solids and liquids in long-standing type 1 diabetes","volume":"90","author":"Russo","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.diabres.2026.113155_b0355","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1210\/clinem\/dgaa854","article-title":"Acceleration of gastric emptying by insulin-induced hypoglycemia is dependent on the degree of hypoglycemia","volume":"106","author":"Murthy","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.diabres.2026.113155_b0360","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/dom.13956","article-title":"Exenatide once weekly slows gastric emptying of solids and liquids in healthy, overweight people at steady-state concentrations","volume":"22","author":"Jones","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.diabres.2026.113155_b0365","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqae155","article-title":"Physiology and pharmacology of effects of GLP-1-based therapies on gastric, biliary and intestinal motility","volume":"166","author":"Jalleh","year":"2024","journal-title":"Endocrinology"},{"issue":"12","key":"10.1016\/j.diabres.2026.113155_b0370","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S2468-1253(17)30285-6","article-title":"Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial","volume":"2","author":"Halawi","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.diabres.2026.113155_b0375","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/dom.14944","article-title":"Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity","volume":"25","author":"Jensterle","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.diabres.2026.113155_b0380","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2337\/dc13-1813","article-title":"Glucagon-like peptide 1 attenuates the acceleration of gastric emptying induced by hypoglycemia in healthy subjects","volume":"37","author":"Plummer","year":"2014","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.diabres.2026.113155_b0385","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1053\/j.gastro.2013.11.044","article-title":"Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass","volume":"146","author":"Salehi","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.diabres.2026.113155_b0390","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaf691","article-title":"Sustained action of imapextide, a glucagon-like peptide-1 receptor antagonist, in healthy volunteers","author":"Fabbrini","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.diabres.2026.113155_b0395","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.2337\/diabetes.53.9.2397","article-title":"Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia","volume":"53","author":"Degn","year":"2004","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.diabres.2026.113155_b0400","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/dom.12473","article-title":"Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4\u2009weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial","volume":"17","author":"Pieber","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.diabres.2026.113155_b0405","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/dom.12398","article-title":"Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus","volume":"17","author":"Hompesch","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.diabres.2026.113155_b0410","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/dom.12817","article-title":"Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: a randomized, open-label, 2-arm parallel comparative, exploratory trial","volume":"19","author":"Yabe","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.diabres.2026.113155_b0415","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1111\/dom.13316","article-title":"Effects on the glucagon response to hypoglycaemia during DPP-4 inhibition in elderly subjects with type 2 diabetes: a randomized, placebo-controlled study","volume":"20","author":"Farngren","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"10.1016\/j.diabres.2026.113155_b0420","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1111\/dom.13422","article-title":"Effect of once-weekly semaglutide on the counterregulatory response to hypoglycaemia in people with type 2 diabetes: a randomized, placebo-controlled, double-blind, crossover trial","volume":"20","author":"Korsatko","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2026.113155_b0425","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1627947","article-title":"Counterregulatory response to hypoglycemia during a hypoglycemic clamp in people with type 2 diabetes treated with tirzepatide","volume":"16","author":"Pieber","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"10.1016\/j.diabres.2026.113155_b0430","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2337\/dc15-1274","article-title":"Effect of the GLP-1 receptor agonist lixisenatide on counterregulatory responses to hypoglycemia in subjects with insulin-treated type 2 diabetes","volume":"39","author":"Farngren","year":"2016","journal-title":"Diabetes Care"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726000744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822726000744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T08:43:29Z","timestamp":1779093809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822726000744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":86,"alternative-id":["S0168822726000744"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113155","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of GLP-1 and incretin-based therapies on counterregulatory responses to hypoglycemia in diabetes mellitus: mechanisms and clinical implications","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2026.113155","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113155"}}